TrialBMC neurology2016

PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury.

Flora M Hammond et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.